This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity

NCT06536023 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Adolescents With Obesity

Interventions

DRUG: IBI362
DRUG: IBI362 placebo

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.